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Aim: Reports concerning changes in hepatitis B virus (HBV)
status and liver function in hepatocellular carcinoma (HCC)
during or after transcatheter arterial chemoembolization
(TACE) have been rare and the results inconsistent. The objec-
tive of this retrospective study was to evaluate these param-
eters in a large cohort of HBV-related HCC patients.
Methods: One hundred and seventy-two hepatitis B surface
antigen positive HCC patients with Child–Pugh grade A or B
liver disease who underwent 228 sessions of TACE were
enrolled, and related clinical and laboratory data were
analyzed.
Results: In total, HBV reactivated in 33 (14.5%), remained
stable in 152 (66.7%) and decreased in 43 (18.8%) sessions.
Univariate analysis revealed that sex and HBV DNA levels
correlated with changes in HBV DNA status after TACE, while
hepatitis B e-antigen (HBeAg), prothrombin time and che-
motherapeutic agents were marginally significant factors.
Multivariate analysis demonstrated that the major factors that
influenced the HBV DNA status were baseline HBV DNA lev-
els(P = 0.0002) and HBeAg (P = 0.0387). A comparison of the
post-TACE (30–90 days) liver function to the baseline revealed
no significant differences. The reactivation group has the
highest rate of exacerbation (12.1%) compared with the stable
group (5.9%) and downregulation group (4.7%).
Conclusion: HBV DNA changes after TACE included reacti-
vated, decreased and stable HBV DNA levels. Although HBV
reactivation did not necessarily result in exacerbation of liver
damage and most HCC patients with Child–Pugh grade A and
B tolerated TACE well, careful post-procedure monitoring and
managing is needed.
Key words: hepatitis B virus reactivation, hepatitis B virus
DNA, hepatocellular carcinoma, liver function, transcatheter
arterial chemoembolization
INTRODUCTION
HEPATOCELLULAR CARCINOMA (HCC) is thesixth most common cancer and the third most
common cause of cancer death worldwide.1 In highly
endemic areas, hepatitis B virus (HBV) infection plays a
primary role in the etiology of HCC and is frequently
observed in HCC patients.2 While curative therapies
including hepatectomy, transplantation and ablation
can be applied to some early stage HCC, transcatheter
arterial chemoembolization (TACE) has become an
important therapeutic modality improving survival in
some carefully selected patients with unresectable
HCC.3,4
It is well known that in HBV-infected patient
treated with systemic chemotherapy for hemato-
logical and some solid tumors HBV can reactivate,
and such flare-ups of HBV have led to fatal results.5
Accordingly, society guidelines now recommend that
hepatitis B surface antigen (HBsAg) positive patients
receive pre-emptive nucleoside/nucleotide analog
(NUC) administration during therapy (regardless of
HBV DNA levels) and for 12 months after cessation of
chemotherapy.6
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However, although HCC has the highest infection
rate of HBV compared to other malignancies7 and the
complication of HBV reactivation is expected to be
more frequently observed with more severe clinical
course, reports concerning HBV status of HCC patients
during or after TACE are rare, and the results have been
controversial. While some studies have demonstrated
HBV reactivation after TACE,8–10 some have not,11–13
and others have shown decreased HBV DNA levels after
TACE.14
The objective of the current retrospective study was to
evaluate changes in HBV DNA levels and liver function
before and after a single session of TACE in HBsAg
positive Child–Pugh grade A and B HCC.
METHODS
Patients
BETWEEN JULY 2005 and March 2007, patients whowere diagnosed with HBsAg positive HCC and
received TACE at the Hepatobiliary Department of Sun
Yat-sen University Cancer Center were retrospectively
recruited in this investigation. Demographic data of
patients were recorded.
Baseline examinations before TACE included serum
HBV DNA quantification, detection of HBsAg, hepatitis
B surface antibody (HBsAb), hepatitis B core antibody
(HBcAb), hepatitis B e-antigen (HBeAg), hepatitis B e
antibody (HBeAb) and anti-hepatitis C virus (HCV)
antibody, serum liver tests (alanine aminotransferase,
ALT; aspartate aminotransferase, AST; alkaline phos-
phatase; total bilirubin, T-bil; and albumin, ALB), crea-
tinine levels, prothrombin time (PT), a-fetoprotein
(AFP) levels, complete blood counts and chest radiog-
raphy. Serum hepatitis B markers and HCV antibody
were tested by commercial enzyme immunoassays
(Auszyme MC Dynamic; Abbott Laboratories, North
Chicago, IL, USA). Serum HBV viral loads were mea-
sured by a quantitative HBV DNA fluorescence poly-
merase chain reaction detection kit (DaAn Gene,
Guangzhou, China) with a lower detection limit of
100 IU/mL. Tumor characteristics and International
Union Against Cancer Tumor–Node–Metastasis stage
were evaluated by imaging. Within 1 week of baseline
examinations, patients received TACE consisting
of chemotherapeutic agents (including epirubicin
[60 mg/session] and/or mitomycin [6 mg/session], car-
boplatin [300 mg/session], lobaplatin [50 mg/session],
floxuridine [500 mg/session]), lipiodol and/or gelfoam
embolization.
To be included in this retrospective study, enrolled
patients were required to have at least 3 months of
follow up. Post-procedure, the same laboratory and
clinical data as obtained at baseline were collected
30–90 days after TACE. The inclusion criteria also
included HBsAg positivity, adequate baseline liver func-
tion (Child–Pugh grade A or B) and adequate renal
function (serum creatinine <124 mmol/L).
Patients with any of the following were excluded: a
history of antiviral therapy prior to the designated
post-TACE tests as mentioned above (30–90 days after
TACE); negative test for HBsAg; evidence of superinfec-
tion with other hepatotropic viruses or HIV; intrahepatic
arteriovenous shunts; loss to follow up within 3 months
after TACE; obstructive jaundice; hepatic encephalopa-
thy; Child–Pugh grade C; any other malignancy; concur-
rent non-malignant severe illness; history of hepatotoxic
medication within 8 weeks prior to current TACE
session; history of corticosteroid administration or any
treatment for HCC within 12 weeks prior to the study;
and sessions with poor data integrity. In total, 172
HBsAg positive HCC patients undergoing 228 sessions
of TACE were enrolled in this study.
TACE procedure
Transcatheter arterial chemoembolization was per-
formed as we previously described.15 When the catheter
tip was advanced to the tumor feeding arteries, one or
several chemotherapeutic agents with mixed lipiodol
were then slowly injected. Gelatin sponge particles were
injected in some sessions if the chemoembolized artery
territory did not show stagnant flow. The selection of
different combinations of anticancer agents, lipiodol
emulsion dosage and use of gelfoam were made based
on a case-by-case basis.
Definitions14,16–18
Hepatitis B virus DNA status changes after TACE for all
patients were grouped into three categories: (i) HBV
reactivation; (ii) HBV downregulation; and (iii) stable
status. HBV reactivation was defined as a 10-fold or
more increase in HBV DNA level compared to baseline
or the appearance of HBV DNA from an undetectable
level at baseline, and post-TACE HBV DNA of more
than 200 IU/mL. HBV downregulation was defined as a
10-fold or more decrease in HBV DNA level compared
to baseline or the disappearance of HBV DNA from a
detectable level at baseline, and the baseline HBV DNA
before TACE were all more than 200 IU/mL. Those
patients that did not fall into either of these categories
were defined as having a “stable status”. Hepatitis was
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defined as a threefold or more increase in serum
ALT levels above the upper limit of normal (normal
<40 IU/L) or an absolute increase of ALT to more than
100 IU/L. Icteric hepatitis was defined by a serum T-bil
level that exceeded twice the reference range (normal
<20.5 mmol/L) in the presence of hepatitis. Exacerbation
of liver damage included both hepatitis and icteric
hepatitis as defined above.
Statistical analysis
Demographic data (mean, standard deviation, sample
size and percentage) were calculated. Analyses were con-
ducted using the independent Student’s t-test, ANOVA,
Student’s paired t-test, c2-test and Fisher’s exact test
when appropriate. Univariate and multivariate analyses
(backward elimination multinomial logistic regression)
were performed to evaluate the possible factors that
related to the changes of HBV DNA and exacerbation of
liver damage after TACE. The following variables that
might correlate with the HBV DNA status and hepatic
exacerbation were evaluated: age, sex, TACE before, ALT,
T-bil, ALB, HBeAg, HBV DNA, AFP, PT, chemotherapeu-
tic agents and Child–Pugh grade (Tables 2,3). Data were
analyzed using SAS ver. 9.1.
RESULTS
Study population
OF THE 228 sessions of TACE, 218 (95.6%) were formales and 10 (4.4%) were for females with an
overall mean age of 49.0 1 11.6 years. The frequency of
chronic HBV infection (confirmed by HBsAg or HBV
DNA positivity prior to the current study) was 88.2%.
One hundred and twenty-seven (55.7%) sessions com-
prised the initial treatment of the HCC. Previous treat-
ments prior to the current TACE session included TACE,
hepatectomy and local thermal ablation. The baseline
HBV DNA values ranged from undetectable (<100 IU/
mL) to 1.8 ¥ 107 IU/mL. When log10 transformed, the
HBV DNA values satisfied conditions for normal distri-
bution with a mean value of 4.0 1 2.2 log10 IU/mL. The
clinical and laboratory features at entry are shown in
Table 1.
Clinical characteristics during the 228
sessions of TACE procedures
Digital subtraction angiography (DSA) showed that
there were 23 (10.1%) sessions with single hepatic
tumor lesions, and 205 (89.9%) sessions with multiple
hepatic lesions. The infused lipiodol dose ranged
Table 1 Baseline characteristics of all 228 sessions of TACE
Baseline characteristics Description
History of HBV infection
Yes 201 (88.2%)
No 27 (11.8%)
Duration of HBV infection (n = 201)
1–5 years 21 (10.4%)
5–10 years 34 (16.9%)
10–20 years 77 (38.3%)
20–30 years 47 (23.4%)




TACE before the current session
Yes 81 (35.5%)
No 147 (64.5%)
Hepatectomy before the current session
Yes 38 (16.7%)
No 190 (83.3%)
Local ablation before the current session
Yes 18 (7.9%)
No 210 (92.1%)
WBC (109/L) 6.7 1 2.4
HBG (g/L) 136.0 1 21.0
PLT (109/L) 177.3 1 95.5
AST (u/L) 66.2 1 60.6
ALT (u/L) 54.2 1 37.4
ALB (g/L) 40.6 1 4.5




PT (s) 12.5 1 1.7
APTT (s) 29.1 1 5.0












AFP, a-fetoprotein; ALB, serum albumin; ALT, alanine
aminotransferase; APTT, activated partial thromboplastin time;
AST, aspartate aminotransferase; HBeAg, hepatitis B e-antigen;
HBG, hemoglobin; HBV, hepatitis B virus; PLT, platelets; PT,
prothrombin time; TACE, transcatheter arterial
chemoembolization; T-bil, total bilirubin; UICC TNM,
International Union Against Cancer Tumor–Node–Metastasis;
WBC, white blood cells.
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5–30 mL with a mean of 15.8 1 8.8 mL. As for the che-
motherapeutic regimens, 58 (25.4%) sessions used a
single agent (epirubicin) while the other 170 (74.6%)
sessions used combinations of chemotherapeutic
agents. Specifically, 94 (41.2%) sessions applied epiru-
bicin, mitomycin and lobaplatin; and 76 (33.4%) ses-
sions applied epirubicin, floxuridine and carboplatin.
Sixty-one sessions (26.8%) applied gelfoam emboliza-
tion while the other 167 sessions (73.2%) did not. All
the recruited TACE sessions were performed without
severe complications during the peri-treatment period.
Changes of HBV DNA status after TACE
As described in the methods, HBV DNA values and the
related liver parameters were evaluated during the
designated 30–90 days (mean: 51.8 1 15.3 days) after





OR 95% CI OR 95% CI
Downregulation vs stable 1.611 1.275–2.035 2.409 0.963–6.029
Reactivation vs stable 1.027 0.853–1.236 3.589 0.991–12.994
Backward elimination multinomial logistic regression was conducted to select variables related to hepatitis B virus (HBV) DNA status
changes with the “stable” status group as a reference. The removal significance level was 0.05. The analyses included HBV DNA status
changes as a dependent factor, while age, sex, transcatheter arterial chemoembolization (TACE) before, alanine aminotransferase, total
bilirubin, albumin, hepatitis B e-antigen, HBV DNA, a-fetoprotein, prothrombin time, chemotherapeutic agents and Child–Pugh grade
were included as independent factors.
†The “positive” category was the reference group.
CI, confidence interval; HBeAg, hepatitis B e-antigen; OR, odds ratio.
Table 2 Univariate analyses for the possible factors correlating to the changes of HBV DNA status after TACE
Variables Stable (n = 152) Reactivation (n = 33) Downregulation (n = 43) P-value
Age (year) 48.6 1 11.6 50.4 1 11.3 49.2 1 11.9 0.7142
Sex 0.0460*
Male 148 32 38
Female 4 1 5
TACE before 0.3327
Yes 59 10 12
No 93 23 31
ALT (U/L) 51.9 1 30.8 53.8 1 59.8 62.4 1 36.4 0.2671
T-bil (mmol/L) 14.6 1 5.9 15.0 1 5.9 15.9 1 7.0 0.4631
ALB (g/L) 40.9 1 4.6 40.6 1 3.9 39.6 1 4.4 0.2434
HBeAg 0.0863
Positive 40 3 9
Negative 112 30 34
HBV DNA (log10 IU/mL) 3.7 1 2.3 3.6 1 1.7 5.3 1 1.4 <0.0001**
AFP (ng/mL) 12 379.2 1 30 367.7 11 953.3 1 30 587.6 12 553.1 1 31 270.8 0.9963
PT (s) 12.3 1 1.6 13.1 1 2.0 12.8 1 2.0 0.0501
Chemotherapeutic agents 0.0527
Epirubicin only 35 6 17
>2 agents 117 27 26
Child–Pugh grade 0.7299
A 148 32 41
B 4 1 2
*Significant differences between stable group and downregulation group.
**Significant differences between stable group and downregulation group, as well as reactivation group and downregulation group.
AFP, a-fetoprotein; ALB, serum albumin; ALT, alanine aminotransferase; HBeAg, hepatitis B e-antigen; HBV, hepatitis B virus; PT,
prothrombin time; TACE, transcatheter arterial chemoembolization; T-bil, total bilirubin.
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TACE. In total, HBV DNA reactivation occurred after
33 sessions (14.5%), maintained a stable status after
152 (66.7%) sessions and HBV DNA downregulation
occurred after 43 (18.8%) sessions.
Univariate analysis (Table 2) revealed that sex and
baseline HBV DNA may correlate with the changes
of HBV DNA status after TACE, while HBeAg, PT and
chemotherapeutic agents showed marginally significant
associations. Specifically, the proportion of females in
the downregulation group was 11.6% (5/43), signifi-
cantly higher than in the stable group (2.6%, 4/152).
HBV DNA values were significantly higher in down-
regulated group (5.3 1 1.4 log10 IU/mL) compared
to reactivated and stable groups (3.6 1 1.7 and
3.7 1 2.3 log10 IU/mL, respectively). The frequency of
HBeAg seropositivity in the reactivated group was 9%
(3/33), lower (marginally significantly) than that of the
stable status group (40/152, 26.3%). The PT was longer
in the reactivation group (13.1 1 2.0 s) than in the
stable group (12.3 1 1.6 s). Reactivation was more
frequent (marginally significantly) in patients that
received combinations of chemotherapeutic agents (27/
33, 81.8%) compared to those patients that had down-
regulation of HBV levels (26/43, 60.5%). Specifically,
Figure 1 shows the correlation between HBV DNA
status and the different combinations of chemothera-
peutic agents. There were no significant differences
among the frequencies of reactivation, stable and
downregulation status of group A (pure epirubicin),
group B (epirubicin, mitomycin and lobaplatin) and
group C (epirubicin, floxuridine and carboplatin). The
results of multinomial logistic regression analysis are
presented in Table 3. The HBV DNA status’ changes
were overall significantly correlated with baseline HBV
DNA levels (P = 0.0002). For one unit (log10 trans-
formed) increase in HBV DNA level, the risk of
downregulation increased significantly (odds ratio
[OR] = 1.611; 95% confidence interval [CI] = 1.275–
2.035; P < 0.0001), but HBV DNA level was not corre-
lated with reactivation (OR = 1.027; 95% CI = 0.853–
1.236; P = 0.7793). The changes of HBV DNA status
were also overall significantly correlated with HBeAg
(P = 0.0387). Compared to the HBeAg positive patients,
the HBeAg negative patients were marginally signifi-
cantly correlated with the increased risks of reactivation
(OR = 3.589; 95% CI = 0.991–12.994; P = 0.0516) or
downregulation (OR = 2.409; 95% CI = 0.963–6.029;
P = 0.0603). Age, sex, TACE before, ALT, T-bil, ALB,
AFP, PT, chemotherapeutic agents and Child–Pugh
grade were not significantly correlated with the changes
of HBV DNA after TACE in the current model.
Changes in the liver tests after TACE as a function of
change in HBV DNA levels are shown in Table 4. There
were no significant differences concerning AST, ALT,
ALB, T-bil, AFP, PT, activated partial thromboplastin
time and Child–Pugh grade. The occurrence rate of exac-
erbation of liver damage was highest in the reactivation
group (4/33, 12.1%), although there were no significant
differences compared to the other two groups (stable
9/152, 5.9%; downregulated 2/43, 4.7%). The post-
TACE HBV DNA value in the reactivated group
(5.6 1 1.3 log10 IU/mL) was significantly higher than the
other two groups (stable 3.7 1 2.3 log10 IU/mL; down-
regulated 3.3 1 1.8 log10 IU/mL).
Comparisons between pre- and post-TACE
clinical and biological characteristics
In addition to testing in the designated time period
(30–90 days after TACE), liver testing was also done
shortly after TACE administration (within 7 days). The
results are listed in Table 5. Compared to the baseline
(Table 1), the mean values of AST, ALT and T-bil
increased significantly soon after TACE (within 7 days).
However, they decreased to levels close to baseline at the


















Figure 1 Various combinations of chemotherapeutic agents
and changes in hepatitis B virus (HBV) DNA status after tran-
scatheter arterial chemoembolization (TACE). (A) Epirubicin
only (reactivation, 6 cases; stable, 35 cases; downregulation, 17
cases). (B) Epirubicin, floxuridine and carboplatin (reactiva-
tion, 17 cases; stable, 61 cases; downregulation, 16 cases).
(C) Epirubicin, floxuridine and lobaplatin (reactivation, 10
cases; stable, 56 cases; downregulation, 10 cases). (Dosages
administrated: epirubicin 60 mg; mitomycin 6 mg; carboplatin
300 mg; lobaplatin 50 mg; floxuridine 500 mg.). There were no
significant differences among groups (A–C) concerning
changes of HBV DNA status. ( ) Reactivation, ( ) stable
status, and ( ) downregulation.
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TACE), and the only significant change concerning liver
tests was a decline in ALB from 40.6 1 4.5 g/L at baseline
to 39.8 1 4.4 g/L after TACE.
Clinical features
The clinical features of the 15 patients with exacerbation
of liver damage after TACE are shown in Table 6. Among
them there were five sessions/patients (patients 11–15)
with icteric hepatitis.
The baseline liver tests of these 15 patients were
fairly favorable, mostly Child–Pugh grade A, except
for patient 6. However, there were six (patients 10–15)
patients that developed into grade B after TACE, and
most of them experienced post-TACE icteric hepatitis.
Hepatitis B e-antigen was positive in three sessions,
and negative in 12 sessions at baseline. Most of these
remained unchanged except patient 7 who changed
from HBeAg negative at baseline to positive after TACE.
The HBV DNA values at baseline ranged from
undetectable (<100 IU/mL) to 1.2 ¥ 106 IU/mL with a
median of 2.0 ¥ 103 IU/mL. HBV DNA reactivated after
four sessions, downregulated after two and remained
stable after nine sessions. HBV DNA values were more
than 200 IU/mL in most (11/15, 73.3%) sessions
Table 4 Comparison of liver tests after TACE among the three groups based on HBV DNA changes
Serum liver tests Stable (n = 152) Reactivation (n = 33) Downregulation (n = 43) P-value
AST (u/L) 65.1 1 61.1 70.9 1 45.3 76.5 1 55.0 NS
ALT (u/L) 52.4 1 40.3 64.7 1 67.4 61.6 1 50.7 NS
ALB (g/L) 39.9 1 4.4 40.0 1 5.2 38.9 1 3.9 NS
T-bil (mmol/L) 14.4 1 9.2 14.4 1 12.1 15.6 1 9.9 NS
AFP (ng/mL) 12 839.8 1 30 815.6 14 897.8 1 33 941.6 16 116.9 1 35 197.5 NS
PT (s) 12.4 1 1.6 12.4 1 1.6 12.7 1 1.5 NS
APTT (s) 29.2 1 5.3 29.9 1 4.8 30.3 1 4.4 NS
HBV DNA (log10 IU/mL) 3.7 1 2.3 5.6 1 1.3 3.3 1 1.8 <0.0001*
Child–Pugh grade (A : B) 148:4 31:2 40:3 NS
Exacerbation of liver damage 9 (5.9%) 4 (12.1%) 2 (4.7%) NS
*Significant differences between reactivation group and stable status group, as well as between reactivation group and downregulation
group.
AFP, a-fetoprotein; ALB, serum albumin; ALT, alanine aminotransferase; APTT, activated partial thromboplastin time; AST, aspartate
aminotransferase; HBV, hepatitis B virus; PT, prothrombin time; TACE, transcatheter arterial chemoembolization; T-bil, total bilirubin.
Table 5 Related laboratory features after TACE (n = 228)
Variables Post-TACE (within 7 days) P* Post-TACE (30–90 days) P*
WBC (109/L) 8.6 1 3.3 <0.05 6.0 1 2.0 <0.05
HBG (g/L) 126.8 1 20.1 <0.05 129.0 1 18.9 <0.05
PLT (109/L) 124.8 1 75.3 <0.05 163.1 1 82.0 <0.05
AST (u/L) 184.7 1 218.3 <0.05 68.1 1 57.9 NS
ALT (u/L) 183.3 1 181.0 <0.05 55.9 1 47.2 NS
ALB (g/L) 37.3 1 4.7 <0.05 39.8 1 4.4 <0.05
T-bil (mmol/L) 30.7 1 18.5 <0.05 14.6 1 9.7 NS
AFP (ng/mL) NA NA 13 755.4 1 32 009.3 NS
PT (s) NA NA 12.5 1 1.6 NS
APTT (s) NA NA 29.5 1 5.1 NS
HBV DNA (log10 IU/mL) NA NA 3.9 1 2.2 NS
HBeAg positive rate NA NA 24.1% (55/228) NS
Child staging (A/B) NA NA 219/9 NS
*Compared to baseline.
AFP, a-fetoprotein; ALB, serum albumin; ALT, alanine aminotransferase; APTT, activated partial thromboplastin time; AST, aspartate
aminotransferase; HBeAg, hepatitis B e-antigen; HBG, hemoglobin; HBV, hepatitis B virus; NA, non-applicable; NS, no significance;
PLT, platelets; PT, prothrombin time; TACE, transcatheter arterial chemoembolization; T-bil, total bilirubin; WBC, white blood cells.
558 X.-M. Lao et al. Hepatology Research 2011; 41: 553–563
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(patients 3–11 and 14–15) after TACE, and lamivudine
or entecavir was initiated in these patients early after the
diagnosis of exacerbation of liver damage.
After supportive and/or antiviral treatment, most of
the liver tests returned to relatively normal levels. Some
of the patients received subsequent treatment (such as
focal ablation, TACE or sorafenib) for HCC. However,
the liver tests of patients 13 and 14 remained elevated
and they died 96 and 102 days after the current TACE,
respectively. Their HBV DNA status remained stable. The
causes of death in these two patients were likely dete-
rioration in liver function and progression of the liver
tumors.
To determine factors related to cases of exacerbation
of liver damage, 12 variables listed in Table 2 and HBV
DNA status changes were analyzed. None of these vari-
ables showed a statistically significant relationship to
exacerbation as determined by univariate or multivari-
ate analysis (data not shown).
DISCUSSION
AS TO THE changes of HBV DNA status after TACE,some studies demonstrated that reactivation did
occur, similar to systemic chemotherapy for hemato-
logical malignancies. Jang et al. demonstrated a 33.7%
rate of HBV reactivation in HCC patients undergoing
repeated transarterial chemo-lipiodolization (with a
mean cycle number of >5).8 Some case reports also
showed that TACE represents a major risk factor for
HBV reactivation in HBV-related HCC patients.10,19,20
However, different or even controversial results were
observed in other reports.11–14 A prospective study
showed that a single session of TACE had little effect on
the incidence of HBV reactivation, and usually the HBV
reactivated patients recovered spontaneously.11 Another
study13 demonstrated that there were no significant
changes of HBV DNA levels between the pre-TACE and
post-TACE stage either in patients with or without exac-
erbation of liver damage. In a Chinese HBV-related HCC
population,14 the positivity rate of HBV DNA decreased
significantly from 71.6% (pre-TACE) to 55.6% (post-
TACE). The controversies of the results may be due to
the differences in study designs, HBV DNA assays, defi-
nitions of HBV reactivation or downregulation, regi-
mens of chemotherapy and patient populations.
To the best of our knowledge, the current report
describes the first large study to evaluate the possible
changes in HBV DNA (including reactivation, down-
regulation and stable status simultaneously) after TACE.
HBV DNA levels remained stable in the majority
(66.7%) of TACE sessions. The reactivation frequency
was 14.5% in our study, lower than that in the treatment
of hematological tumor reported previously.17 As to the
reasons for this discrepancy, we believe that chemo-
therapeutic agents and being corticosteroid-free may
play key roles because of their distinct influences on the
extent of immunosuppression. It has been reported that
immune suppression of greater intensity carried a higher
risk for HBV reactivation, while mild chemotherapy
carried a lower risk.21,22 The dosages of the chemoth-
erapeutic agents we used were less than that of systemic
chemotherapy for hematological malignancies. More
importantly, no monoclonal antibodies such as ritux-
imab (anti-CD20), alemtuzumab (anti-CD52) and
infliximab (anti-tumor necrosis factor) were adminis-
trated in our current study. These agents can cause
strong and long-lasting immunosuppression, and
contribute to a high risk of HBV reactivation, and sub-
sequent fulminant hepatitis.5,17 Moreover, no corticos-
teroids were administrated in the recruited patients in
our current study, while “steroid-free” chemotherapy
has been proposed to minimize the risk of HBV reacti-
vation.5,23 Therefore, the agents used in our TACE are
likely to be considered as low intensity chemotherapy
with mild immune suppression, which may account for
a relatively lower rate of HBV reactivation.
In our current study, 81.8% (27/33) of the reactiva-
tion cases administrated combinations of chemothera-
peutic agents, while 76.9% (117/152) of the stable
cases and 60.5% (26/43) of the downregulation cases
received combinations of chemotherapy (Table 2).
But this difference was not statistically significant, and
Figure 1 also demonstrates that there were no signifi-
cant differences among the frequencies of reactivation,
stable and downregulation status of the different groups
of combinations of chemotherapeutic agents. This is
probably due to the relatively low intensity chemo-
therapy with mild immune suppression in the current
study discussed above.
Contrary to the results of some studies,8,18 the absence
of HBeAg positivity appeared to be a risk factor for HBV
reactivation compared to the HBV stability by multivari-
ate analyses in the current study. The reason for the
discrepancy is not clear, which may be correlated with
the different study designs, regimens of chemotherapy,
and patient populations and selection bias. In Yeo
et al.’s study18 of cancer patients undergoing systemic
cytotoxic chemotherapy, the recruited cancer type
included breast, gastrointestinal, lung, lymphoma, head
and neck, and gynecological cancer, while HCC was
excluded. The risk factors for HBV reactivation of these
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non-HCC cancer patients with HBV infection included
male sex, younger age, HBeAg seropositivity and the
diagnosis of lymphoma. But in another Yeo et al. study16
of HCC patients undergoing systemic cytotoxic chemo-
therapy, the only identifiable associated risk factor for
HBV reactivation was elevated pretreatment ALT while
HBeAg showed no influences. In Jang et al.’s study,8
HCC patients undergoing repeated transarterial chemo-
lipiodolization (with a mean cycle number of >5), there
were higher proportions (22.9%) of Child B/C patients,
which are different in our current study (single TACE
session and only 3.1% patients with Child B). Another
possible reason may be attributed to the presence of the
precore/core promoter HBV mutants.24 One more pos-
sibility is that fluctuation of HBV DNA might easily
develop among HBeAg negative patients, as compared
with HBeAg positive patients. However, this needs to be
further investigated. In addition, viral load is more likely
to be closely related to HBeAg status because HBeAg is a
marker of active viral replication, and HBeAg negativity
and low baseline HBV DNA were correlated with reac-
tivation in the present study. Therefore, caution should
be exercised in HBV-related HCC patients regardless of
the HBeAg status.
In 18.8% of sessions, there was HBV DNA downregu-
lation after TACE. As far as we know, only one other
study14 reported HBV DNA downregulation after TACE.
In other studies, the terminology “non-reactivation”
would pertain to both the “downregulation” and
“stable” groups described in our study. Univariate
(Table 2) and multivariate analyses (Table 3) showed
that a high HBV viral load at baseline was a predictive
factor for downregulation, a result similar to that of Xu
et al. which demonstrated that patients with HBV DNA
of more than 105 copies/mL had greater decreases in
HBV viral load. That study also showed that the HBV
DNA decrease was correlated with decreases in AFP. The
mechanism by which downregulation of HBV occurs is
unclear. Explanations include a natural course of chronic
hepatitis B even without exposure to TACE,25 natural
spontaneous fluctuation in HBV DNA levels and pos-
sible tumor shrinkage after TACE.
Interestingly, sex also correlated with the HBV DNA
downregulation in the univariate analysis. In the down-
regulation group, 11.6% of them were female (5/43),
while only 2.6% were female in the stable group
(4/152). In Yeo and Lok et al.’s studies,18,26 sex appeared
to be a risk factor for HBV DNA reactivation after che-
motherapy for non-HCC malignancies. The mechanism
concerning the relationship between sex and HBV DNA
changes remains unclear,
The laboratory parameters concerning the liver (ALT,
AST and T-bil) were transiently increased within 1 week
post-TACE (Table 5), which may reflect the effects of
TACE on hepatic vasculature. The transiently increased
indices returned to baseline levels within a few weeks or
months, similar to the report of Ahmad et al.12 Caturelli
et al.27 reported that tumor necrosis did not cause wors-
ening of liver function after TACE in patients with Child
A or B liver disease. A prospective study in Hong Kong
also demonstrated that in the majority of their patients,
liver tests after TACE returned to pretreatment levels
with time, and only a minority of patients eventually
developed irreversible liver failure.28 Usually, most
patients with favorable liver function have been able to
tolerate more than one session of TACE.4,28 Of the 15
patients with exacerbation of liver damage in our study,
in only two patients did liver function not recover after
TACE (Table 6) and HBV DNA status remained stable in
both cases. However, although the occurrence of exac-
erbation of liver damage was not significantly different
among the three groups (Table 4) and HBV DNA status
changes did not show a statistically significant relation-
ship with it, the reactivation group had the highest
rate of exacerbation (12.1%) compared with the stable
group (5.9%) and downregulation group (4.7%). These
data indicated that careful post-TACE monitoring is
needed, especially in those with HBV DNA reactivation.
Another possible factor leading to liver damage is the
direct effect of TACE (usually ischemia). Huo et al.29
described a 45% incidence of ischemic hepatitis after
TACE. Although ischemic hepatitis usually occurs
immediately after embolization and persists for a vari-
able period of time, it is difficult to judge the relation-
ship in hepatitis that is attributable to viral reactivation.
In Huo et al.’s opinion,30 overt hepatitis may be due to
either ischemia or viral reactivation, depending on the
time point of serum biochemistry measurement, and
both components may occur simultaneously in a sub-
stantial proportion of patients. To our best knowledge,
there is no clear cut-off time point to divide ischemic
hepatitis and non-ischemic hepatitis. As Huo et al.30
demonstrated, the cause of overt hepatitis after TACE
might be multifactorial in the usual clinical setting.
One more concern is that HBV DNA values after TACE
were more than 200 IU/mL in 73.3% of cases with exac-
erbation of liver damage although its occurrence was
not significantly related to HBV DNA status changes.
These patients were treated with nucleoside analogs,
and most of them recovered (Table 6). As to the antivi-
ral therapy in HBV-related HCC patients undergoing
TACE, there have been few reports concerning these
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specific populations. Several studies and case reports
demonstrated the efficacy of NUC in the prophylaxis
and treatment of reactivation of HBV hepatitis.
In summary, HBV DNA levels after TACE included
reactivation, downregulation and stable groups. In the
present study, HBeAg negativity and low baseline HBV
DNA were correlated with reactivation. Although HBV
reactivation did not necessarily result in deterioration of
hepatic functions, careful monitoring and management
are needed in case of the potential occurrence. Con-
versely, those with exacerbation of liver function did not
always have signs of HBV reactivation. All these data
would raise caution to physicians involved in the treat-
ment of HCC. One drawback of the current retrospective
study is that serum HBV DNA and liver function could
not be monitored over time or serially. Additional
studies with longer and serial follow up concerning the
correlation between viral kinetics and host immunity are
needed. However, this study did reveal that most HBV-
related HCC patients with Child–Pugh grade A and B are
able to tolerate TACE with careful management.
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